No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for PepGen Inc. (PEPG) stock was $2.32 as of Oct 6, 2026, 3:14 PM EDT, down 1.91% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -53.8% · 3-year avg -21.6%/yr
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Biotechnology · Boston, MA
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.27
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.26
vs Estimate
$-0.28
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1PEPG | $160.13M | $2.31 | -1.91% | -53.83% | N/A | N/A | N/A |
| 2NERV | $160.02M | $3.43 | +3.45% | +57.75% | -22.14% | -29.77% | vs PEPG |
| 3LFMDP | $159.22M | $23.35 | +2.14% | +6.17% | +10.80% | N/A | vs PEPG |
| 4CHRS | $162.23M | $1.05 | -6.25% | -31.58% | -41.38% | -26.92% | vs PEPG |
| 5QTRX | $162.80M | $3.46 | -9.29% | -37.20% | -39.63% | N/A | vs PEPG |
| 6INGN | $156.90M | $5.79 | -2.44% | -31.21% | -32.83% | -20.74% | vs PEPG |
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 8 analysts
Average Price Target
$10.19
+340.1% upside
Low
$2.50
Current
$2.31
High
$20.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.29 | $-0.27 | $-0.26 | 5 |
| Quarter ending Dec 2026 | $-0.47 | $-0.29 | $-0.19 | 5 |
| Quarter ending Mar 2027 | $-0.24 | $-0.24 | $-0.24 | 3 |
| Quarter ending Jun 2027 | $-0.21 | $-0.21 | $-0.21 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.27 | $-1.06 | $-0.93 | 6 |
| FY 2027 | $-1.53 | $-1.09 | $-0.70 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $37.46M | $37.46M | $37.46M | 7 |
| FY 2027 | $4.61M | $4.61M | $4.61M | 4 |
